Daihan Scientific

At a glance

Daihan Scientific filed 25 disclosures in the last 12 months, including 7 insider, 3 5% holder and 1 contract. The most recent key filing was on Oct 29: Director bought 27,053 sh on the market at an average ₩3,695, Oct 28–29.

Revenue for 2025 was ₩81.1B, up 13.1% on 2024. Operating margin was 6.8% against 5.9% a year earlier. Debt was 27% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩39.2B and operating profit of ₩3B.

The 2025 annual report lists 120 employees with an average tenure of 8.7 years and average pay of ₩49.4M, #1475 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩116.8M each on average. It paid ₩125 per common share in cash dividends, against ₩60 a year earlier (+108.3%). 서정구 and related parties held 37.43% at year end.

From the 2025 annual report

Staff: 120 (83 men, 37 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩5.9B. Directors and auditors: 5, paid ₩583.9M in total.

Dividends (common shares)

Largest shareholder

서정구 holds 9.17%; with 20 related parties the group holds 37.43% of common shares at year end (from 37.40% at the start of the year).

Auditor: 태성회계법인 · opinion: Unqualified.

Rankings: Dividend growth #69 of 917

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

1 new supply contract worth 6% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary